Glenmark Pharmaceuticals has received $15 million from Salix Pharmaceuticals, Inc, USA. This is as per an agreement for advance against commitment fee which is to cover Glenmark's risks associated with upgrading its manufacturing facilities to meet Salix's anticipated increased requirements in demand for Crofelemer.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment